TSE:2802Food
How Investors Are Reacting To Ajinomoto (TSE:2802) Doubling Gene Therapy Productivity After Share Buyback
In recent news, Ajinomoto Co., Inc. announced the completion of a buyback program totaling 27,902,000 shares (2.83% of shares outstanding) for ¥99.99 billion and revealed a collaboration with subsidiary Forge Biologics to double viral vector manufacturing productivity in gene therapy through a new culture media supplement.
This partnership directly targets the fast-growing gene therapy CDMO segment and signals Ajinomoto's intent to strengthen its presence in healthcare innovation as mapped...